CognitiveNot approvedEvidence tier: Human Observational

Delta-Sleep Inducing Peptide Analogs (DSIP Analogs)

Last updated October 21, 2026. Approval line checked October 21, 2026. Compounding sources checked October 10, 2026.

FDA status

Not approved

Not approved. This record is not an FDA-approved drug product. Approval, where it exists, is specific to a drug product, indication, and route.

FDA primary source on file

Evidence tier

Human Observational. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 2/5. 543 PubMed citations indexed.

Delta-Sleep Inducing Peptide Analogs (DSIP Analogs) in the literature

DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a nonapeptide that modulates adrenergic receptor sensitivity in the pineal gland (particularly alpha-1 adrenoceptors regulating N-acetyltransferase) and i

What the literature studies

Cognitive Research

Evidence tier

Human Observational

Compounding record

Status not verified

Confidence
2/5

Regulatory record

Status not verified. Status not verified. Exact FDA substance context: FDA names Emideltide (DSIP): Nomination withdrawn. This listing is not a classification of all DSIP analogs. Previously in Category 2; FDA still identifies potential significant safety risks for the named withdrawn substance. Withdrawal is not FDA approval or a determination of safety or compounding eligibility. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.

Regulatory source checked October 10, 2026. This compounding label is separate from the approval line above.

FDA primary source 1 FDA primary source 2

Regulatory context and verification limits are documented below.

Questions

Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.